{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:11:44Z","timestamp":1791231104409,"version":"4.1.0"},"reference-count":5,"publisher":"BMJ","issue":"e3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2022,9,16]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>Pulmonary lymphangitic carcinomatosis (PLC) is a type of lymphangitic spread of cancer cells, from a primary site to the pulmonary vasculature and lymphatics. Corticosteroids are recommended for PLC by clinical guidelines, although scientific evidence for this traditional practice is still lacking. We report a patient with lung cancer who developed clinically diagnosed PLC and was successfully treated with steroid treatment. The pulmonary shadows suggestive of PLC were remarkably improved, as well as her symptom. Corticosteroids are worth trying when PLC is clinically suspected.<\/jats:p>","DOI":"10.1136\/spcare-2022-003983","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T17:20:47Z","timestamp":1666891247000},"page":"e951-e952","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Corticosteroids for pulmonary lymphangitic carcinomatosis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-4836","authenticated-orcid":false,"given":"Takayuki","family":"Takimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2024121022580618000_13.e3.e951.1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.62.2.179"},{"key":"2024121022580618000_13.e3.e951.2","doi-asserted-by":"crossref","first-page":"v169","DOI":"10.1093\/annonc\/mdv306","article-title":"Treatment of dyspnoea in advanced cancer patients: ESMO clinical practice guidelines","volume":"26 Suppl 5","author":"Kloke","year":"2015","journal-title":"Ann Oncol"},{"key":"2024121022580618000_13.e3.e951.3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1089\/jpm.2016.0145","article-title":"Treatment recommendations for respiratory symptoms in cancer patients: clinical guidelines from the Japanese Society for palliative medicine","volume":"19","author":"Yamaguchi","year":"2016","journal-title":"J Palliat Med"},{"key":"2024121022580618000_13.e3.e951.4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpainsymman.2015.10.023","article-title":"Dexamethasone for dyspnea in cancer patients: a pilot double-blind, randomized, controlled trial","volume":"52","author":"Hui","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"2024121022580618000_13.e3.e951.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4785.639"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2022-003983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T07:17:54Z","timestamp":1733901474000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2022-003983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":5,"journal-issue":{"issue":"e3","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/spcare-2022-003983"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2022-003983","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}